← All stocks

NewAmsterdam Pharma Co N.V.

NAMS Net selling

CIK 0001936258 #1687 in the set updated 17 Sep 2026

Bought (12 mo)

$226.50K

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$62.00M

$457.69K on a plan · $57.71M straight out of an exercise

Sold at will

$3.83M

6 of 42 sales

Net

−$61.77M

−$3.61M against sales at will

By person

17 insiders · 44 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Davidson Michael H.

Chief Executive Officer

$226.50K (1)

$25.33M (9) scheduled

−$25.10M

1,078,638

0.9023%

$24.43M

+31.8%

Kooij Louise Frederika

Chief Accounting Officer

—

$16.75M (16) scheduled

−$16.75M

24,353

0.0204%

$551.60K

—

Kastelein Johannes Jacob Pieter

Chief Scientific Officer

—

$14.26M (7) scheduled

−$14.26M

122,802

0.1027%

$2.78M

—

Somaiya Mayur Ian

Chief Financial Officer

—

$3.43M (6) scheduled

−$3.43M

58,382

0.0488%

$1.32M

—

LANGE LOUIS G

Director

—

$2.19M (3)

−$2.19M

10,360

0.0087%

$234.65K

−58.4%

Smither John W

Director

—

$40.51K (1)

−$40.51K

8,760

0.0073%

$198.41K

—

ForGrowth NAP B.V.

10% owner

—

10,656,172

8.91%

$241.36M

−9.9%

Topper James N

Director

—

3,028,524

2.53%

$68.60M

+0.7%

Marino Michael F III

See Remarks

—

55,000

0.0460%

$1.25M

—

Kling Douglas F

Chief Operating Officer

—

44,000

0.0368%

$996.60K

—

JONES WILLIAM A JR

Chief Commercial Officer

—

43,000

0.0360%

$973.95K

—

Audet Juliette Berangere

See Remarks

—

15,104

0.0126%

$342.11K

—

Gulfo Adele M.

Director

—

14,260

0.0119%

$322.99K

—

Lewis William

Director

—

10,360

0.0087%

$234.65K

—

McKenna Mark C.

Director

—

10,360

0.0087%

$234.65K

—

van der Kamp Hilde Johanna

Director

—

10,360

0.0087%

$234.65K

—

Gunning Robert William

Vice President, Controller

—

3,200

0.0027%

$72.48K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Davidson Michael H.

14 Sep 2026

Chief Executive Officer

Buy

10,000

$22.65

$226.50K

Show all 44 transactions →

What was left out

Form 4 filings counted 28

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 4

Sales straight out of an exercise 32

Sales at will 6

Transactions with no price 1

Shares from compensation/vesting 1,987,219

History held since 3 Jan 2024